Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Peripheral Neuropathy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Peripheral Neuropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Peripheral Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Peripheral Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Peripheral Neuropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Diabetic Peripheral Neuropathy Overview 7 Therapeutics Development 8 Pipeline Products for Diabetic Peripheral Neuropathy - Overview 8 Pipeline Products for Diabetic Peripheral Neuropathy - Comparative Analysis 9 Diabetic Peripheral Neuropathy - Therapeutics under Development by Companies 10 Diabetic Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 11 Diabetic Peripheral Neuropathy - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Diabetic Peripheral Neuropathy - Products under Development by Companies 15 Diabetic Peripheral Neuropathy - Products under Investigation by Universities/Institutes 16 Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development 17 Acorda Therapeutics, Inc. 17 Astellas Pharma Inc. 18 Cebix Incorporated 19 Pfizer Inc. 20 ViroMed Co., Ltd. 21 Diabetic Peripheral Neuropathy - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 Antimunocel - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ASP-8477 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 BNV-222 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 capsaicin - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 CBX-129801 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Drug for Pain - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 ketoprofen - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 NRD-135SE1 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 PF-05089771 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 VM-202 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Diabetic Peripheral Neuropathy - Recent Pipeline Updates 48 Diabetic Peripheral Neuropathy - Dormant Projects 53 Diabetic Peripheral Neuropathy - Discontinued Products 54 Diabetic Peripheral Neuropathy - Product Development Milestones 55 Featured News & Press Releases 55 Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 55 Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 56 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2015 8 Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H2 2015 9 Number of Products under Development by Companies, H2 2015 10 Number of Products under Investigation by Universities/Institutes, H2 2015 11 Comparative Analysis by Late Stage Development, H2 2015 12 Comparative Analysis by Clinical Stage Development, H2 2015 13 Comparative Analysis by Early Stage Development, H2 2015 14 Products under Development by Companies, H2 2015 15 Products under Investigation by Universities/Institutes, H2 2015 16 Diabetic Peripheral Neuropathy - Pipeline by Acorda Therapeutics, Inc., H2 2015 17 Diabetic Peripheral Neuropathy - Pipeline by Astellas Pharma Inc., H2 2015 18 Diabetic Peripheral Neuropathy - Pipeline by Cebix Incorporated, H2 2015 19 Diabetic Peripheral Neuropathy - Pipeline by Pfizer Inc., H2 2015 20 Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co., Ltd., H2 2015 21 Assessment by Monotherapy Products, H2 2015 22 Number of Products by Stage and Target, H2 2015 24 Number of Products by Stage and Mechanism of Action, H2 2015 26 Number of Products by Stage and Route of Administration, H2 2015 28 Number of Products by Stage and Molecule Type, H2 2015 30 Diabetic Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H2 2015 48 Diabetic Peripheral Neuropathy - Dormant Projects, H2 2015 53 Diabetic Peripheral Neuropathy - Discontinued Products, H2 2015 54
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
